SCHEMBL8205231

SCHEMBL8205231

Cc1ccc(C[C@H](NC(=O)[C@H]2O[C@@H]2C(=O)NCC(=O)O)C(=O)NCc2ccc3ccccc3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB1 P20618 1/20 0.48
▸ PSMB5 P28074 1/20 0.48
▸ PSMB2 P49721 1/20 0.48
▸ FCER2 P06734 2/20 0.48
▸ MMP9 P14780 2/20 0.45
▸ MMP8 P22894 2/20 0.45
▸ MMP2 P08253 1/20 0.45
▸ CTSS P25774 4/20 0.43
▸ CTSB P07858 3/20 0.43
▸ CTSL P07711 3/20 0.43
▸ CTSK P43235 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ ACE P12821 2/20 0.42
▸ MME P08473 1/20 0.42
▸ CPA1 P15085 1/20 0.42
▸ ACE2 Q9BYF1 1/20 0.42
▸ ATM Q13315 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NPY5R Q15761 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8206608 1.00 PSMB1 (0.48) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL14123205 1.00 PSMB1 (0.48) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL15579616 0.87 PSMB5 (0.45) PSMB5LCKATML3MBTL1HTT
SCHEMBL15579516 0.87 PSMB5 (0.45) PSMB5LCKATML3MBTL1HTT
SCHEMBL14123030 0.87 SMO (0.41) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL14123234 0.87 SMO (0.41) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL8209423 0.86 CAPN1 (0.48) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL14123223 0.86 CAPN1 (0.48) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL14123427 0.86 CAPN1 (0.48) PSMB1PSMB5PSMB2FCER2MMP9
SCHEMBL14122989 0.82 PSMB1 (0.45) PSMB1PSMB5PSMB2FCER2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176841-A1 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-07-24 — — US disclosed
US-20080176841-A1 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-07-24 — — US disclosed
WO-2008042480-A2 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176841-A1 EPOXIDE INHIBITORS OF CYSTEINE PROTEASES SERPINB1, EPHX1, EPX PSMB1 242/4885PSMB5 203/4885PSMB2 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback